Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2014-03-21 Legal Proceedings Report
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Simeprevir erhåller positivt utlåtande från den europeiska läkemedelsmyndigheten avseende behandling av vuxna patienter med kronisk hepatit C inom EU
Legal Proceedings Report Classification · 99% confidence The document is a press release from Medivir AB announcing that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for the drug Simeprevir for treating chronic Hepatitis C in the EU. This type of announcement, detailing regulatory progress, clinical trial results, and market strategy updates, is characteristic of an Investor Presentation (IP) or a general regulatory/corporate update. Since it is a detailed announcement about a significant regulatory milestone (positive opinion/recommendation) rather than just a brief notice of publication (RPA) or a general filing (RNS), and it contains substantial information about the drug's efficacy and market context, 'Investor Presentation' (IP) is the most fitting category, as these often include such strategic updates. However, given the specific nature of regulatory progress announcements, it could also be considered a specialized regulatory filing update. Comparing the options, 'IP' (Investor Presentation) often encompasses detailed strategic updates like this, which are presented to investors. If a more specific regulatory update category existed, it would be preferred, but among the given choices, IP captures the strategic, detailed nature of the announcement better than the general 'RNS' or the specific 'ER'/'IR'. Since it is a detailed announcement of a regulatory step, I will classify it as an Investor Presentation (IP) as these often contain such material updates, although it borders on a Regulatory Filing (RNS). Given the depth of clinical data summary, IP is slightly stronger than RNS.
2014-03-21 Swedish
Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "Press Release" dated March 21, 2014, announcing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the marketing authorization for the drug simeprevir in the European Union. This type of announcement, detailing a significant regulatory milestone or clinical trial result outside of routine financial reporting periods (like quarterly or annual results), typically falls under general regulatory announcements or investor relations news. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change, the most appropriate general category for a significant, non-financial regulatory update is 'Regulatory Filings' (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) as it contains substantive news, not just a notice that a report is available.
2014-03-21 English
Nya resultat från fas III-studier med Simeprevir har presenterats vid The Conference of the Asian Pacific Association for the Study of the Liver
Earnings Release Classification · 95% confidence The document is a press release from Medivir AB announcing new results from Phase III clinical trials (ATTAIN, QUEST-1, QUEST-2, PROMISE) for their drug Simeprevir, presented at a medical conference (APASL). It details efficacy and safety data (SVR12 rates, adverse events) and includes quotes from management and contact information for Investor Relations (IR). This content structure—announcing scientific/clinical progress and providing key data points—is characteristic of an Earnings Release (ER) or a general announcement related to investor information. Since it focuses on clinical trial results rather than comprehensive financial statements (like a 10-K or IR) or a formal transcript (CT), and it is an initial announcement of results, the most appropriate classification is Earnings Release (ER). It is not a formal regulatory filing like 10-K or a short RPA, as it contains substantial detail about the results themselves. FY 2014
2014-03-17 Swedish
New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL)
Earnings Release Classification · 95% confidence The document is a press release announcing the presentation of new Phase III clinical trial data for the drug simeprevir at a medical conference (APASL). It details efficacy and safety results from studies like ATTAIN, QUEST-1, QUEST-2, and PROMISE. This type of announcement, focusing on scientific data presentation and clinical trial outcomes, is characteristic of an Earnings Release (ER) or a general press release. Since it is not a full annual report (10-K), a formal quarterly report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate classification is Earnings Release (ER), as these often include operational and clinical updates alongside financial highlights, or Regulatory Filing (RNS) if it's purely scientific news. Given the structure (headline, key findings, executive quote, detailed study results, contact info, boilerplate about the company), it strongly resembles an Earnings Release or a scientific update press release. Since 'ER' covers initial announcements of periodical financial results and related operational news, and this is a significant data update, ER is a strong fit. However, if the primary focus is purely scientific data presentation outside of a standard quarterly earnings cycle, RNS might be considered. Given the context of financial reporting databases, clinical trial updates are often bundled with ERs or treated as significant news releases. I will classify it as an Earnings Release (ER) because it reports on key performance indicators (trial results) and includes a boilerplate section typical of such announcements, even if financial figures are absent. The document length (9050 chars) is substantial, ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements. FY 2014
2014-03-17 English
Valberedningens förslag till ny styrelse inför årsstämman 2014
AGM Information Classification · 98% confidence The document is titled 'Valberedningens förslag till ny styrelse inför årsstämman 2014' (The Nomination Committee's proposal for a new board of directors for the 2014 Annual General Meeting). It details the composition of the Nomination Committee and explicitly proposes re-election and new appointments for the Board of Directors, including biographies of the proposed new members. This content directly relates to the governance structure and the election of directors, which falls under Board/Management Information (MANG) or potentially Governance Information (CGR). However, the focus is specifically on the *proposal* for the board composition ahead of the AGM, which is a key component of management/board announcements. Since it is a proposal for the board, MANG is the most precise fit, as it concerns changes in the company's board structure/members. It is not the AGM presentation itself (AGM-R) or the final voting results (DVA).
2014-03-14 Swedish
The Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General Meeting, for a new Board of Directors
Board/Management Information Classification · 99% confidence The document explicitly discusses the 'Nomination Committee's proposal' regarding the 'new Board of Directors' to be appointed at the 'upcoming 2014 Annual General Meeting'. This content directly relates to the composition and proposed changes to the company's governing body (Board of Directors) and is presented in the context of an AGM. This aligns perfectly with the 'Board/Management Information' (MANG) category, which covers announcements of changes in the board of directors or senior management. While it mentions the AGM, the core subject is the board proposal itself, not the voting results (DVA) or the AGM presentation materials (AGM-R). Given the focus on proposing new and re-electing existing board members and detailing their extensive biographies, MANG is the most precise fit.
2014-03-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.